Stock Fundamentals

AI Research Report

Generate a comprehensive financial analysis report powered by AI

AKBA.US Logo

AKBA.US - Current Price

$1.40

Company Information

▼
Company Name
Akebia Ther
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US00972D1054
CIK: 0001517022
CUSIP: 00972D105
Currency: USD
Full Time Employees: 181
Phone: 617 871 2098
Website: https://www.akebia.com
Fiscal Year End: December
IPO Date: Mar 20, 2014
Description:

Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. Its product portfolio includes Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent (DD) and non-dialysis dependent (NDD) patients; and Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD and the treatment of iron deficiency anemia in adult patients with NDD-CKD. The company is also developing AKB-9090 for treating cardiac surgery-related acute kidney injury and acute respiratory distress syndrome; and AKB-10108 for the treatment of retinopathy of prematurity in neonates. The company has license and collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of Vafseo in Japan and other Asian countries. Akebia Therapeutics, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Address:

245 First Street, Cambridge, MA, United States, 02142

Directors & Officers

▼
Name Title Year Born
Mr. John P. Butler MBA CEO, President & Director 1964
Mr. Erik John Ostrowski M.B.A. Chief Business Officer, Senior VP, CFO & Treasurer 1972
Dr. Steven Keith Burke M.D. Senior VP and Chief Research & Development Officer 1961
Mr. Nicholas Grund Senior VP & Chief Commercial Officer 1970
Mr. Richard C. Malabre Chief Accounting Officer 1961
Ms. Kimberly Garko Senior VP & Chief Technical Officer NA
Ms. Tracey Vetterick Vice President of Portfolio Strategy & Corporate Administration NA
Mercedes Carrasco Senior Director of Investor & Corporate Communications NA
Ms. Carolyn Rucci Senior VP of Legal, General Counsel & Secretary NA
Ms. Meredith Bowman Senior VP & Chief People Officer NA

Shares Statistics

▼
Shares Outstanding: 265.37M
Shares Float: 260.02M
% Insiders: 355.60%
% Institutions: 4,976.50%
Short % Float: 13.73%

Valuation Metrics

▼
Enterprise Value: $257.65M
Trailing P/E: 0.00
Forward P/E: 7.37

Financial Highlights

▼
Market Cap: $371.51M
EBITDA: $32.25M
PEG Ratio: $0.00
Book Value: $0.16
Earnings/Share: $-0.08
Profit Margin: -7.07%
Operating Margin: 7.57%
ROA (TTM): 4.80%
ROE (TTM): -553.45%
Revenue (TTM): $225.07M
Revenue/Share (TTM): $0.92
Earnings Growth (YOY): 0.00%
Revenue Growth (YOY): 57.00%

Stock Price History

▼

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

▼

Revenue & Net Income

Operating Expenses

Balance Sheet Overview

Earnings Per Share (EPS)

Earnings History

▼
Date EPS Actual EPS Estimate Difference Surprise %
Dec 31, 2025 0.00 -0.04 N/A 10,000.00%
Sep 30, 2025 0.00 -0.04 N/A 10,555.56%
Jun 30, 2025 0.03 -0.02 N/A 23,350.00%
Mar 31, 2025 0.02 -0.08 N/A 13,087.50%
Dec 31, 2024 -0.10 -0.08 N/A -3,333.33%
Sep 30, 2024 -0.10 -0.06 N/A -6,666.67%
Jun 30, 2024 -0.04 -0.05 N/A 2,000.00%
Mar 31, 2024 -0.09 -0.08 N/A -1,250.00%
Dec 31, 2023 0.00 -0.04 N/A 10,800.00%
Sep 30, 2023 -0.08 -0.08 N/A 0.00%
Jun 30, 2023 -0.06 -0.02 N/A -20,000.00%
Mar 31, 2023 -0.14 -0.15 N/A 666.67%
Dec 31, 2022 -0.04 -0.19 N/A 7,894.74%
Sep 30, 2022 -0.28 -0.15 N/A -8,666.67%
Jun 30, 2022 0.23 -0.31 N/A 17,419.35%
Mar 31, 2022 -0.35 -0.29 N/A -2,068.97%
Dec 31, 2021 -0.40 -0.33 N/A -2,121.21%
Sep 30, 2021 -0.34 -0.32 N/A -625.00%
Jun 30, 2021 -0.51 -0.32 N/A -5,937.50%
Mar 31, 2021 -0.45 -0.29 N/A -5,517.24%
Dec 31, 2020 -0.60 -0.40 N/A -5,000.00%
Sep 30, 2020 -0.42 -0.17 N/A -14,705.88%
Jun 30, 2020 -0.44 -0.50 N/A 1,200.00%
Mar 31, 2020 -0.47 -0.62 N/A 2,419.35%
Dec 31, 2019 -0.79 -0.47 N/A -6,808.51%
Sep 30, 2019 -0.46 -0.43 N/A -697.67%
Jun 30, 2019 -0.49 -0.32 N/A -5,312.50%
Mar 31, 2019 -0.62 -0.40 N/A -5,500.00%
Dec 31, 2018 -0.23 -0.24 N/A 416.67%
Sep 30, 2018 -0.46 -0.64 N/A 2,812.50%
Jun 30, 2018 -0.60 -0.51 N/A -1,764.71%
Mar 31, 2018 -0.48 -0.59 N/A 1,864.41%
Dec 31, 2017 0.25 -0.35 N/A 17,142.86%
Sep 30, 2017 -0.49 -0.51 N/A 392.16%
Jun 30, 2017 -0.53 -0.87 N/A 3,908.05%
Mar 31, 2017 -1.15 -0.39 N/A -19,487.18%
Dec 31, 2016 -0.99 0.77 N/A -22,857.14%
Sep 30, 2016 -0.96 -1.09 N/A 1,192.66%
Jun 30, 2016 -0.95 -0.57 N/A -6,666.67%
Mar 31, 2016 -0.70 -0.42 N/A -6,666.67%
Dec 31, 2015 -0.66 -0.28 N/A -13,571.43%
Sep 30, 2015 -0.68 -0.52 N/A -3,076.92%
Jun 30, 2015 -0.40 -0.51 N/A 2,156.86%
Mar 31, 2015 -0.53 -0.57 N/A 701.75%
Dec 31, 2014 -0.52 -0.65 N/A 2,000.00%
Sep 30, 2014 -0.47 -0.45 N/A -444.44%
Jun 30, 2014 -0.39 -0.52 N/A 2,500.00%
Mar 31, 2014 -4.35 -0.38 N/A -104,473.68%

Balance Sheet (Yearly)

▼
Date Cash Total Debt Total Assets Total Liabilities Total Equity
2024-12-31 $51.87M $N/A $220.67M $269.86M $-49.19M
2023-12-31 $42.93M $N/A $241.70M $272.29M $-30.58M
2022-12-31 $90.47M $N/A $356.05M $350.82M $5.23M
2021-12-31 $149.80M $N/A $529.35M $455.34M $74.01M
2020-12-31 $229.09M $N/A $644.14M $396.52M $247.62M
2019-12-31 $147.71M $N/A $771.20M $376.44M $394.76M
2018-12-31 $104.64M $N/A $996.54M $360.61M $635.93M
2017-12-31 $70.16M $N/A $364.25M $244.92M $119.33M
2016-12-31 $187.34M $N/A $300.22M $232.10M $68.12M
2015-12-31 $49.78M $N/A $142.94M $11.94M $131.00M
2014-12-31 $32.78M $N/A $111.00M $6.92M $104.08M
2013-12-31 $21.22M $N/A $34.66M $3.91M $30.76M
2012-12-31 $1.64M $N/A $2.24M $4.92M $-2.68M

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Jun 30, 2025 N/A N/A N/A N/A N/A N/A
Jun 09, 2025 N/A N/A N/A N/A N/A N/A
Jun 04, 2025 N/A N/A N/A N/A N/A N/A
Feb 03, 2025 N/A N/A N/A N/A N/A N/A
Feb 03, 2025 N/A N/A N/A N/A N/A N/A
Feb 03, 2025 N/A N/A N/A N/A N/A N/A
Feb 03, 2025 N/A N/A N/A N/A N/A N/A

Watchlist

0

No stocks in watchlist